Radiolabeled Compounds for Diagnosis and Treatment of Cancer
Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developi...
Spremljeno u:
| Daljnji autori: | |
|---|---|
| Format: | Poglavlje knjige |
| Izdano: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Teme: | |
| Online pristup: | Get Fullteks DOAB: description of the publication |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
| LEADER | 04102naaaa2201021uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_77048 | ||
| 005 | 20220111 | ||
| 020 | |a books978-3-0365-2426-9 | ||
| 020 | |a 9783036524276 | ||
| 020 | |a 9783036524269 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2426-9 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PN |2 bicssc | |
| 100 | 1 | |a Kumar, Krishan |4 edt | |
| 700 | 1 | |a Kumar, Krishan |4 oth | |
| 245 | 1 | 0 | |a Radiolabeled Compounds for Diagnosis and Treatment of Cancer |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (262 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Chemistry |2 bicssc | |
| 653 | |a positron emission tomography (PET) | ||
| 653 | |a pyrazoles | ||
| 653 | |a fluorine-18 | ||
| 653 | |a radionuclides | ||
| 653 | |a PET probes | ||
| 653 | |a imaging pharmaceuticals | ||
| 653 | |a hypopharyngeal cancer | ||
| 653 | |a 188Re-liposome | ||
| 653 | |a repeated therapy | ||
| 653 | |a NGS | ||
| 653 | |a microRNA | ||
| 653 | |a aprepitant | ||
| 653 | |a radiopharmaceuticals | ||
| 653 | |a neurokinin 1 receptor antagonist | ||
| 653 | |a radionuclide chelators | ||
| 653 | |a kidney uptake | ||
| 653 | |a cleavable linkers | ||
| 653 | |a neutral endopeptidase (NEP) | ||
| 653 | |a renal brush border enzymes | ||
| 653 | |a prostate-specific membrane antigen (PSMA) | ||
| 653 | |a cancer imaging and therapy | ||
| 653 | |a somatostatin analogs | ||
| 653 | |a radiolabeling | ||
| 653 | |a radionuclide therapy | ||
| 653 | |a imaging | ||
| 653 | |a adrenergic receptor | ||
| 653 | |a positron emission tomography | ||
| 653 | |a radiotracer | ||
| 653 | |a cholecystokinin-2 receptor | ||
| 653 | |a minigastrin | ||
| 653 | |a molecular imaging | ||
| 653 | |a targeted radiotherapy | ||
| 653 | |a lutetium-177 | ||
| 653 | |a EpCAM | ||
| 653 | |a radionuclide | ||
| 653 | |a SPECT | ||
| 653 | |a iodine | ||
| 653 | |a PIB | ||
| 653 | |a breast | ||
| 653 | |a cancer | ||
| 653 | |a PET | ||
| 653 | |a target-specific biomolecules | ||
| 653 | |a immunoPET imaging pharmaceuticals | ||
| 653 | |a production processes | ||
| 653 | |a 124I-labeled monoclonal antibodies | ||
| 653 | |a radiotracers | ||
| 653 | |a AAZTA | ||
| 653 | |a scandium-44 | ||
| 653 | |a FAP | ||
| 653 | |a SA | ||
| 653 | |a DPP | ||
| 653 | |a PREP | ||
| 653 | |a radioiodine labeling | ||
| 653 | |a radioiodination | ||
| 653 | |a biomolecules | ||
| 653 | |a peptides | ||
| 653 | |a proteins | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a 123,124,125,131I-labeled molecules and biomolecules | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4658 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/77048 |7 0 |z DOAB: description of the publication |